Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma

被引:68
作者
Bedikian, Agop Y. [1 ]
Johnson, Marcella M. [1 ]
Warneke, Carla L. [1 ]
Papadopoulos, Nicholas E. [1 ]
Kim, Kevin [1 ]
Hwu, Wen-Jen [1 ]
Mclntyre, Susan [1 ]
Hwu, Patrick [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
关键词
melanoma; chemotherapy; biochemotherapy; interleukin-2; survival;
D O I
10.1080/07357900802027073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This retrospective analysis aimed to identify the prognostic factors that influenced long-term survival of patients with metastatic melanoma. The medical records for 616 chemo-naive patients who were treated with systemic therapy on eight phase II/III clinical trials were reviewed. Clinical characteristics, disease stage, metastatic sites, baseline serum albumin, LDH, and response to treatment were compared between the treatment groups and significant prognostic factors were identified. Cox proportional-hazards regression analysis identified treatment with biochemotherapy, younger age, normal baseline serum albumin and LDH levels, ECOG P.S. < 2 and absence of visceral metastasis as favorable prognostic factors for long-term survival.
引用
收藏
页码:624 / 633
页数:10
相关论文
共 57 条
[31]   Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma [J].
Johnston, SRD ;
Constenla, DO ;
Moore, J ;
Atkinson, H ;
A'Hern, RP ;
Dadian, G ;
Riches, PG ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 1998, 77 (08) :1280-1286
[32]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[33]   Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments:: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin [J].
Keilholz, U ;
Martus, P ;
Punt, CJA ;
Kruit, W ;
Mooser, G ;
Schadendorf, D ;
Liénard, D ;
Dummer, R ;
Koller, J ;
Voit, C ;
Eggermont, AMM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (11) :1501-1511
[34]   Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group [J].
Keilholz, U ;
Punt, CJA ;
Gore, M ;
Kruit, W ;
Patel, P ;
Lienard, D ;
Thomas, J ;
Proebstle, TM ;
Schmittel, A ;
Schadendorf, D ;
Velu, T ;
Negrier, S ;
Kleeberg, U ;
Lehman, F ;
Suciu, S ;
Eggermont, AMM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6747-6755
[35]   Results of interleukin-2-based treatment in advanced melanoma:: A case record-based analysis of 631 patients [J].
Keilholz, U ;
Conradt, C ;
Legha, SS ;
Khayat, D ;
Scheibenbogen, C ;
Thatcher, N ;
Goey, SH ;
Gore, M ;
Dorval, T ;
Hancock, B ;
Punt, CJA ;
Dummer, R ;
Avril, MF ;
Bröcker, EB ;
Benhammouda, A ;
Eggermont, AMM ;
Pritsch, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2921-2929
[36]   SEQUENTIAL CHEMOIMMUNOTHERAPY WITH CISPLATIN, INTERLEUKIN-2, AND INTERFERON ALFA-2A FOR METASTATIC MELANOMA [J].
KHAYAT, D ;
BOREL, C ;
TOURANI, JM ;
BENHAMMOUDA, A ;
ANTOINE, E ;
RIXE, O ;
VUILLEMIN, E ;
BAZEX, PA ;
THILL, L ;
FRANKS, R ;
AUCLERC, G ;
SOUBRANE, C ;
BANZET, P ;
WEIL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2173-2180
[37]   Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma [J].
Kim, KB ;
Eton, O ;
East, MJ ;
Hodges, C ;
Papadopoulos, NE ;
Grimm, EA ;
Bedikian, AY .
CANCER, 2004, 101 (03) :596-603
[38]  
Legha S, 1993, J CLIN ONCOL, V12, P388
[39]  
LEGHA SS, 1989, CANCER, V64, P2024, DOI 10.1002/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO
[40]  
2-V